Elekta AB (publ)
Elekta AB (publ) (EKTAY) Stock Competitors & Peer Comparison
See (EKTAY) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EKTAY | $4.78 | -1.65% | 1.8B | 68.26 | $0.07 | +0.48% |
| SRTOY | $20.52 | +0.00% | 199.6B | 75.98 | $0.27 | +0.37% |
| ESLOF | $298.58 | +0.53% | 137.3B | 49.79 | $5.98 | +1.52% |
| ESLOY | $147.77 | -0.76% | 136.3B | 49.58 | $2.98 | +1.52% |
| MECNY | $88.63 | +0.00% | 107.8B | N/A | N/A | N/A |
| SOAGY | $42.02 | -0.59% | 68.5B | 120.06 | $0.35 | +0.20% |
| RSMDF | $24.77 | +0.24% | 40.8B | 27.83 | $0.89 | +0.76% |
| HOCPF | $119.01 | -9.93% | 40.5B | 30.44 | $3.91 | +0.91% |
| HOCPY | $116.20 | -8.86% | 40.1B | 29.87 | $3.91 | +0.44% |
| TRUMF | $17.90 | +0.00% | 26.4B | 33.15 | $0.54 | +0.99% |
Stock Comparison
EKTAY vs SRTOY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SRTOY has a market cap of 199.6B. Regarding current trading prices, EKTAY is priced at $4.78, while SRTOY trades at $20.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SRTOY's P/E ratio is 75.98. In terms of profitability, EKTAY's ROE is +0.02%, compared to SRTOY's ROE of +0.05%. Regarding short-term risk, EKTAY is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SRTOY's competition here
EKTAY vs ESLOF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, ESLOF has a market cap of 137.3B. Regarding current trading prices, EKTAY is priced at $4.78, while ESLOF trades at $298.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas ESLOF's P/E ratio is 49.79. In terms of profitability, EKTAY's ROE is +0.02%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to ESLOF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ESLOF's competition here
EKTAY vs ESLOY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, ESLOY has a market cap of 136.3B. Regarding current trading prices, EKTAY is priced at $4.78, while ESLOY trades at $147.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas ESLOY's P/E ratio is 49.58. In terms of profitability, EKTAY's ROE is +0.02%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to ESLOY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ESLOY's competition here
EKTAY vs MECNY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, MECNY has a market cap of 107.8B. Regarding current trading prices, EKTAY is priced at $4.78, while MECNY trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas MECNY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to MECNY's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to MECNY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MECNY's competition here
EKTAY vs SOAGY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SOAGY has a market cap of 68.5B. Regarding current trading prices, EKTAY is priced at $4.78, while SOAGY trades at $42.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SOAGY's P/E ratio is 120.06. In terms of profitability, EKTAY's ROE is +0.02%, compared to SOAGY's ROE of +0.05%. Regarding short-term risk, EKTAY is less volatile compared to SOAGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SOAGY's competition here
EKTAY vs RSMDF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, RSMDF has a market cap of 40.8B. Regarding current trading prices, EKTAY is priced at $4.78, while RSMDF trades at $24.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas RSMDF's P/E ratio is 27.83. In terms of profitability, EKTAY's ROE is +0.02%, compared to RSMDF's ROE of +0.26%. Regarding short-term risk, EKTAY is more volatile compared to RSMDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check RSMDF's competition here
EKTAY vs HOCPF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, HOCPF has a market cap of 40.5B. Regarding current trading prices, EKTAY is priced at $4.78, while HOCPF trades at $119.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas HOCPF's P/E ratio is 30.44. In terms of profitability, EKTAY's ROE is +0.02%, compared to HOCPF's ROE of +0.21%. Regarding short-term risk, EKTAY is less volatile compared to HOCPF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check HOCPF's competition here
EKTAY vs HOCPY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, HOCPY has a market cap of 40.1B. Regarding current trading prices, EKTAY is priced at $4.78, while HOCPY trades at $116.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas HOCPY's P/E ratio is 29.87. In terms of profitability, EKTAY's ROE is +0.02%, compared to HOCPY's ROE of +0.20%. Regarding short-term risk, EKTAY is less volatile compared to HOCPY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check HOCPY's competition here
EKTAY vs TRUMF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, TRUMF has a market cap of 26.4B. Regarding current trading prices, EKTAY is priced at $4.78, while TRUMF trades at $17.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas TRUMF's P/E ratio is 33.15. In terms of profitability, EKTAY's ROE is +0.02%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, EKTAY is less volatile compared to TRUMF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TRUMF's competition here
EKTAY vs TRUMY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, TRUMY has a market cap of 25.1B. Regarding current trading prices, EKTAY is priced at $4.78, while TRUMY trades at $17.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas TRUMY's P/E ratio is 32.07. In terms of profitability, EKTAY's ROE is +0.02%, compared to TRUMY's ROE of +0.09%. Regarding short-term risk, EKTAY is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TRUMY's competition here
EKTAY vs CLPBY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, CLPBY has a market cap of 21.5B. Regarding current trading prices, EKTAY is priced at $4.78, while CLPBY trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas CLPBY's P/E ratio is 29.90. In terms of profitability, EKTAY's ROE is +0.02%, compared to CLPBY's ROE of +0.27%. Regarding short-term risk, EKTAY is less volatile compared to CLPBY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CLPBY's competition here
EKTAY vs CLPBF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, CLPBF has a market cap of 20.8B. Regarding current trading prices, EKTAY is priced at $4.78, while CLPBF trades at $92.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas CLPBF's P/E ratio is 29.49. In terms of profitability, EKTAY's ROE is +0.02%, compared to CLPBF's ROE of +0.27%. Regarding short-term risk, EKTAY is less volatile compared to CLPBF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CLPBF's competition here
EKTAY vs SAUHF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SAUHF has a market cap of 19.8B. Regarding current trading prices, EKTAY is priced at $4.78, while SAUHF trades at $124.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SAUHF's P/E ratio is 33.51. In terms of profitability, EKTAY's ROE is +0.02%, compared to SAUHF's ROE of +0.14%. Regarding short-term risk, EKTAY is less volatile compared to SAUHF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SAUHF's competition here
EKTAY vs SDMHF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SDMHF has a market cap of 19.4B. Regarding current trading prices, EKTAY is priced at $4.78, while SDMHF trades at $199.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SDMHF's P/E ratio is 74.25. In terms of profitability, EKTAY's ROE is +0.02%, compared to SDMHF's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to SDMHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SDMHF's competition here
EKTAY vs SAUHY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SAUHY has a market cap of 19.2B. Regarding current trading prices, EKTAY is priced at $4.78, while SAUHY trades at $12.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SAUHY's P/E ratio is 33.53. In terms of profitability, EKTAY's ROE is +0.02%, compared to SAUHY's ROE of +0.14%. Regarding short-term risk, EKTAY is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SAUHY's competition here
EKTAY vs SARTF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SARTF has a market cap of 14B. Regarding current trading prices, EKTAY is priced at $4.78, while SARTF trades at $184.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SARTF's P/E ratio is 106.51. In terms of profitability, EKTAY's ROE is +0.02%, compared to SARTF's ROE of +0.05%. Regarding short-term risk, EKTAY is less volatile compared to SARTF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SARTF's competition here
EKTAY vs SSSGY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SSSGY has a market cap of 14B. Regarding current trading prices, EKTAY is priced at $4.78, while SSSGY trades at $42.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SSSGY's P/E ratio is 121.46. In terms of profitability, EKTAY's ROE is +0.02%, compared to SSSGY's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to SSSGY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SSSGY's competition here
EKTAY vs OCPNF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, OCPNF has a market cap of 13.6B. Regarding current trading prices, EKTAY is priced at $4.78, while OCPNF trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas OCPNF's P/E ratio is 17.54. In terms of profitability, EKTAY's ROE is +0.02%, compared to OCPNF's ROE of +0.16%. Regarding short-term risk, EKTAY is less volatile compared to OCPNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check OCPNF's competition here
EKTAY vs SUVPF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SUVPF has a market cap of 13.5B. Regarding current trading prices, EKTAY is priced at $4.78, while SUVPF trades at $210.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SUVPF's P/E ratio is 120.85. In terms of profitability, EKTAY's ROE is +0.02%, compared to SUVPF's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to SUVPF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SUVPF's competition here
EKTAY vs FSPKF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, FSPKF has a market cap of 11.7B. Regarding current trading prices, EKTAY is priced at $4.78, while FSPKF trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas FSPKF's P/E ratio is 52.66. In terms of profitability, EKTAY's ROE is +0.02%, compared to FSPKF's ROE of +0.28%. Regarding short-term risk, EKTAY is more volatile compared to FSPKF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check FSPKF's competition here
EKTAY vs SSMXY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SSMXY has a market cap of 10.3B. Regarding current trading prices, EKTAY is priced at $4.78, while SSMXY trades at $16.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SSMXY's P/E ratio is 28.53. In terms of profitability, EKTAY's ROE is +0.02%, compared to SSMXY's ROE of +0.12%. Regarding short-term risk, EKTAY is more volatile compared to SSMXY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SSMXY's competition here
EKTAY vs SSMXF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SSMXF has a market cap of 9.5B. Regarding current trading prices, EKTAY is priced at $4.78, while SSMXF trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SSMXF's P/E ratio is 26.38. In terms of profitability, EKTAY's ROE is +0.02%, compared to SSMXF's ROE of +0.12%. Regarding short-term risk, EKTAY is less volatile compared to SSMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SSMXF's competition here
EKTAY vs YPHDF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, YPHDF has a market cap of 7.3B. Regarding current trading prices, EKTAY is priced at $4.78, while YPHDF trades at $535.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas YPHDF's P/E ratio is 67.14. In terms of profitability, EKTAY's ROE is +0.02%, compared to YPHDF's ROE of +0.13%. Regarding short-term risk, EKTAY is more volatile compared to YPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check YPHDF's competition here
EKTAY vs CNVVF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, CNVVF has a market cap of 7.1B. Regarding current trading prices, EKTAY is priced at $4.78, while CNVVF trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas CNVVF's P/E ratio is 31.61. In terms of profitability, EKTAY's ROE is +0.02%, compared to CNVVF's ROE of +0.16%. Regarding short-term risk, EKTAY is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CNVVF's competition here
EKTAY vs CNVVY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, CNVVY has a market cap of 6.3B. Regarding current trading prices, EKTAY is priced at $4.78, while CNVVY trades at $12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas CNVVY's P/E ratio is 29.17. In terms of profitability, EKTAY's ROE is +0.02%, compared to CNVVY's ROE of +0.16%. Regarding short-term risk, EKTAY is less volatile compared to CNVVY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CNVVY's competition here
EKTAY vs FLMNY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, FLMNY has a market cap of 5.3B. Regarding current trading prices, EKTAY is priced at $4.78, while FLMNY trades at $12.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas FLMNY's P/E ratio is 27.82. In terms of profitability, EKTAY's ROE is +0.02%, compared to FLMNY's ROE of +0.17%. Regarding short-term risk, EKTAY is more volatile compared to FLMNY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check FLMNY's competition here
EKTAY vs FLMNF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, FLMNF has a market cap of 5.2B. Regarding current trading prices, EKTAY is priced at $4.78, while FLMNF trades at $61.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas FLMNF's P/E ratio is 27.61. In terms of profitability, EKTAY's ROE is +0.02%, compared to FLMNF's ROE of +0.17%. Regarding short-term risk, EKTAY is less volatile compared to FLMNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check FLMNF's competition here
EKTAY vs ADDLF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, ADDLF has a market cap of 4.9B. Regarding current trading prices, EKTAY is priced at $4.78, while ADDLF trades at $42.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas ADDLF's P/E ratio is 61.76. In terms of profitability, EKTAY's ROE is +0.02%, compared to ADDLF's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ADDLF's competition here
EKTAY vs CZMWF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, CZMWF has a market cap of 4.9B. Regarding current trading prices, EKTAY is priced at $4.78, while CZMWF trades at $56.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas CZMWF's P/E ratio is 27.23. In terms of profitability, EKTAY's ROE is +0.02%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to CZMWF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CZMWF's competition here
EKTAY vs CZMWY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, CZMWY has a market cap of 4.7B. Regarding current trading prices, EKTAY is priced at $4.78, while CZMWY trades at $53.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas CZMWY's P/E ratio is 26.25. In terms of profitability, EKTAY's ROE is +0.02%, compared to CZMWY's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to CZMWY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CZMWY's competition here
EKTAY vs AHICF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, AHICF has a market cap of 4.4B. Regarding current trading prices, EKTAY is priced at $4.78, while AHICF trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas AHICF's P/E ratio is 59.89. In terms of profitability, EKTAY's ROE is +0.02%, compared to AHICF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to AHICF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check AHICF's competition here
EKTAY vs SHWGF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SHWGF has a market cap of 3.4B. Regarding current trading prices, EKTAY is priced at $4.78, while SHWGF trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SHWGF's P/E ratio is 12.67. In terms of profitability, EKTAY's ROE is +0.02%, compared to SHWGF's ROE of +0.09%. Regarding short-term risk, EKTAY is less volatile compared to SHWGF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SHWGF's competition here
EKTAY vs ANSLY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, ANSLY has a market cap of 2.9B. Regarding current trading prices, EKTAY is priced at $4.78, while ANSLY trades at $79.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas ANSLY's P/E ratio is 24.38. In terms of profitability, EKTAY's ROE is +0.02%, compared to ANSLY's ROE of +0.04%. Regarding short-term risk, EKTAY is more volatile compared to ANSLY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ANSLY's competition here
EKTAY vs TCHBF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, TCHBF has a market cap of 2.7B. Regarding current trading prices, EKTAY is priced at $4.78, while TCHBF trades at $211.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas TCHBF's P/E ratio is 32.25. In terms of profitability, EKTAY's ROE is +0.02%, compared to TCHBF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to TCHBF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check TCHBF's competition here
EKTAY vs ANSLF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, ANSLF has a market cap of 2.6B. Regarding current trading prices, EKTAY is priced at $4.78, while ANSLF trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas ANSLF's P/E ratio is 22.22. In terms of profitability, EKTAY's ROE is +0.02%, compared to ANSLF's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to ANSLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ANSLF's competition here
EKTAY vs TCGGY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, EKTAY is priced at $4.78, while TCGGY trades at $36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas TCGGY's P/E ratio is 27.27. In terms of profitability, EKTAY's ROE is +0.02%, compared to TCGGY's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to TCGGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TCGGY's competition here
EKTAY vs BOEUF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, BOEUF has a market cap of 2.2B. Regarding current trading prices, EKTAY is priced at $4.78, while BOEUF trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas BOEUF's P/E ratio is 147.41. In terms of profitability, EKTAY's ROE is +0.02%, compared to BOEUF's ROE of +0.18%. Regarding short-term risk, EKTAY is more volatile compared to BOEUF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BOEUF's competition here
EKTAY vs EKTAF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, EKTAF has a market cap of 1.8B. Regarding current trading prices, EKTAY is priced at $4.78, while EKTAF trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas EKTAF's P/E ratio is 83.33. In terms of profitability, EKTAY's ROE is +0.02%, compared to EKTAF's ROE of +0.02%. Regarding short-term risk, EKTAY is more volatile compared to EKTAF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check EKTAF's competition here
EKTAY vs GRRMF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, GRRMF has a market cap of 1.7B. Regarding current trading prices, EKTAY is priced at $4.78, while GRRMF trades at $46.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas GRRMF's P/E ratio is 22.60. In terms of profitability, EKTAY's ROE is +0.02%, compared to GRRMF's ROE of +0.05%. Regarding short-term risk, EKTAY is less volatile compared to GRRMF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check GRRMF's competition here
EKTAY vs NPRRF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, NPRRF has a market cap of 1.5B. Regarding current trading prices, EKTAY is priced at $4.78, while NPRRF trades at $8.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas NPRRF's P/E ratio is 43.32. In terms of profitability, EKTAY's ROE is +0.02%, compared to NPRRF's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to NPRRF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check NPRRF's competition here
EKTAY vs TDVXF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, TDVXF has a market cap of 1.3B. Regarding current trading prices, EKTAY is priced at $4.78, while TDVXF trades at $12.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas TDVXF's P/E ratio is 84.33. In terms of profitability, EKTAY's ROE is +0.02%, compared to TDVXF's ROE of +0.39%. Regarding short-term risk, EKTAY is less volatile compared to TDVXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TDVXF's competition here
EKTAY vs TGLVY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, TGLVY has a market cap of 1.2B. Regarding current trading prices, EKTAY is priced at $4.78, while TGLVY trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas TGLVY's P/E ratio is 60.00. In terms of profitability, EKTAY's ROE is +0.02%, compared to TGLVY's ROE of +0.02%. Regarding short-term risk, EKTAY is less volatile compared to TGLVY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TGLVY's competition here
EKTAY vs BITGF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, EKTAY is priced at $4.78, while BITGF trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas BITGF's P/E ratio is 45.50. In terms of profitability, EKTAY's ROE is +0.02%, compared to BITGF's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to BITGF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BITGF's competition here
EKTAY vs PBHDF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, PBHDF has a market cap of 1.1B. Regarding current trading prices, EKTAY is priced at $4.78, while PBHDF trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, EKTAY's ROE is +0.02%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to PBHDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check PBHDF's competition here
EKTAY vs SHWGY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SHWGY has a market cap of 1B. Regarding current trading prices, EKTAY is priced at $4.78, while SHWGY trades at $3.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SHWGY's P/E ratio is 13.88. In terms of profitability, EKTAY's ROE is +0.02%, compared to SHWGY's ROE of +0.09%. Regarding short-term risk, EKTAY is more volatile compared to SHWGY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SHWGY's competition here
EKTAY vs NNCSF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, NNCSF has a market cap of 743.9M. Regarding current trading prices, EKTAY is priced at $4.78, while NNCSF trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas NNCSF's P/E ratio is 81.67. In terms of profitability, EKTAY's ROE is +0.02%, compared to NNCSF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to NNCSF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check NNCSF's competition here
EKTAY vs KSRBF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, KSRBF has a market cap of 686.6M. Regarding current trading prices, EKTAY is priced at $4.78, while KSRBF trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas KSRBF's P/E ratio is 3.86. In terms of profitability, EKTAY's ROE is +0.02%, compared to KSRBF's ROE of +0.03%. Regarding short-term risk, EKTAY is more volatile compared to KSRBF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check KSRBF's competition here
EKTAY vs JNDOF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, JNDOF has a market cap of 531M. Regarding current trading prices, EKTAY is priced at $4.78, while JNDOF trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas JNDOF's P/E ratio is 47.40. In terms of profitability, EKTAY's ROE is +0.02%, compared to JNDOF's ROE of +0.20%. Regarding short-term risk, EKTAY is less volatile compared to JNDOF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check JNDOF's competition here
EKTAY vs HGYMF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, HGYMF has a market cap of 524.8M. Regarding current trading prices, EKTAY is priced at $4.78, while HGYMF trades at $24.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas HGYMF's P/E ratio is 33.81. In terms of profitability, EKTAY's ROE is +0.02%, compared to HGYMF's ROE of +0.02%. Regarding short-term risk, EKTAY is more volatile compared to HGYMF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check HGYMF's competition here
EKTAY vs SAFLF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SAFLF has a market cap of 520.2M. Regarding current trading prices, EKTAY is priced at $4.78, while SAFLF trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SAFLF's P/E ratio is 21.50. In terms of profitability, EKTAY's ROE is +0.02%, compared to SAFLF's ROE of +0.05%. Regarding short-term risk, EKTAY is less volatile compared to SAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SAFLF's competition here
EKTAY vs SAFLY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SAFLY has a market cap of 515.5M. Regarding current trading prices, EKTAY is priced at $4.78, while SAFLY trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SAFLY's P/E ratio is 19.08. In terms of profitability, EKTAY's ROE is +0.02%, compared to SAFLY's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to SAFLY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SAFLY's competition here
EKTAY vs SPMXF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, EKTAY is priced at $4.78, while SPMXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, EKTAY's ROE is +0.02%, compared to SPMXF's ROE of -0.05%. Regarding short-term risk, EKTAY is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SPMXF's competition here
EKTAY vs CLHLF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, EKTAY is priced at $4.78, while CLHLF trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, EKTAY's ROE is +0.02%, compared to CLHLF's ROE of +0.12%. Regarding short-term risk, EKTAY is more volatile compared to CLHLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CLHLF's competition here
EKTAY vs GUERF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, GUERF has a market cap of 281M. Regarding current trading prices, EKTAY is priced at $4.78, while GUERF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas GUERF's P/E ratio is 8.19. In terms of profitability, EKTAY's ROE is +0.02%, compared to GUERF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to GUERF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check GUERF's competition here
EKTAY vs TSNLF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, TSNLF has a market cap of 252.4M. Regarding current trading prices, EKTAY is priced at $4.78, while TSNLF trades at $5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas TSNLF's P/E ratio is 33.06. In terms of profitability, EKTAY's ROE is +0.02%, compared to TSNLF's ROE of +0.21%. Regarding short-term risk, EKTAY is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TSNLF's competition here
EKTAY vs OPSSF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, EKTAY is priced at $4.78, while OPSSF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, EKTAY's ROE is +0.02%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, EKTAY is more volatile compared to OPSSF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OPSSF's competition here
EKTAY vs EEOIF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, EKTAY is priced at $4.78, while EEOIF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, EKTAY's ROE is +0.02%, compared to EEOIF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to EEOIF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check EEOIF's competition here
EKTAY vs UEEC Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, UEEC has a market cap of 21.1M. Regarding current trading prices, EKTAY is priced at $4.78, while UEEC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas UEEC's P/E ratio is -8.21. In terms of profitability, EKTAY's ROE is +0.02%, compared to UEEC's ROE of +1.31%. Regarding short-term risk, EKTAY is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check UEEC's competition here
EKTAY vs GVDI Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, GVDI has a market cap of 15.8M. Regarding current trading prices, EKTAY is priced at $4.78, while GVDI trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas GVDI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, EKTAY is more volatile compared to GVDI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check GVDI's competition here
EKTAY vs OTCFF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, OTCFF has a market cap of 13.4M. Regarding current trading prices, EKTAY is priced at $4.78, while OTCFF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas OTCFF's P/E ratio is -9.64. In terms of profitability, EKTAY's ROE is +0.02%, compared to OTCFF's ROE of -7.85%. Regarding short-term risk, EKTAY is more volatile compared to OTCFF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OTCFF's competition here
EKTAY vs TEVNF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, TEVNF has a market cap of 7.5M. Regarding current trading prices, EKTAY is priced at $4.78, while TEVNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas TEVNF's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, EKTAY is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TEVNF's competition here
EKTAY vs RSCF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, RSCF has a market cap of 6.4M. Regarding current trading prices, EKTAY is priced at $4.78, while RSCF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas RSCF's P/E ratio is -7.50. In terms of profitability, EKTAY's ROE is +0.02%, compared to RSCF's ROE of +0.08%. Regarding short-term risk, EKTAY is less volatile compared to RSCF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check RSCF's competition here
EKTAY vs IMTH Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, IMTH has a market cap of 5.8M. Regarding current trading prices, EKTAY is priced at $4.78, while IMTH trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas IMTH's P/E ratio is -0.29. In terms of profitability, EKTAY's ROE is +0.02%, compared to IMTH's ROE of +2.29%. Regarding short-term risk, EKTAY is less volatile compared to IMTH. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check IMTH's competition here
EKTAY vs BLMHF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, EKTAY is priced at $4.78, while BLMHF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, EKTAY's ROE is +0.02%, compared to BLMHF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to BLMHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BLMHF's competition here
EKTAY vs TUTH Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, TUTH has a market cap of 4.9M. Regarding current trading prices, EKTAY is priced at $4.78, while TUTH trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas TUTH's P/E ratio is -2.05. In terms of profitability, EKTAY's ROE is +0.02%, compared to TUTH's ROE of +0.31%. Regarding short-term risk, EKTAY is less volatile compared to TUTH. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TUTH's competition here
EKTAY vs YBGJ Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, YBGJ has a market cap of 4.8M. Regarding current trading prices, EKTAY is priced at $4.78, while YBGJ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas YBGJ's P/E ratio is -2.00. In terms of profitability, EKTAY's ROE is +0.02%, compared to YBGJ's ROE of +3.46%. Regarding short-term risk, EKTAY is more volatile compared to YBGJ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check YBGJ's competition here
EKTAY vs PXMVF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, EKTAY is priced at $4.78, while PXMVF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, EKTAY's ROE is +0.02%, compared to PXMVF's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check PXMVF's competition here
EKTAY vs CBSC Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, CBSC has a market cap of 4.5M. Regarding current trading prices, EKTAY is priced at $4.78, while CBSC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas CBSC's P/E ratio is -3.99. In terms of profitability, EKTAY's ROE is +0.02%, compared to CBSC's ROE of +1.21%. Regarding short-term risk, EKTAY is less volatile compared to CBSC. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CBSC's competition here
EKTAY vs MCDA Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, EKTAY is priced at $4.78, while MCDA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas MCDA's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to MCDA's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to MCDA. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MCDA's competition here
EKTAY vs ECIA Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, ECIA has a market cap of 4.1M. Regarding current trading prices, EKTAY is priced at $4.78, while ECIA trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas ECIA's P/E ratio is -17.35. In terms of profitability, EKTAY's ROE is +0.02%, compared to ECIA's ROE of -0.33%. Regarding short-term risk, EKTAY is less volatile compared to ECIA. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ECIA's competition here
EKTAY vs NSTGQ Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, EKTAY is priced at $4.78, while NSTGQ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check NSTGQ's competition here
EKTAY vs OJSY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, EKTAY is priced at $4.78, while OJSY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas OJSY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to OJSY's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to OJSY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OJSY's competition here
EKTAY vs PDMI Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, EKTAY is priced at $4.78, while PDMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas PDMI's P/E ratio is -0.01. In terms of profitability, EKTAY's ROE is +0.02%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, EKTAY is more volatile compared to PDMI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check PDMI's competition here
EKTAY vs REMI Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, REMI has a market cap of 200K. Regarding current trading prices, EKTAY is priced at $4.78, while REMI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas REMI's P/E ratio is -1.00. In terms of profitability, EKTAY's ROE is +0.02%, compared to REMI's ROE of -0.08%. Regarding short-term risk, EKTAY is more volatile compared to REMI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check REMI's competition here
EKTAY vs WHSI Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, EKTAY is priced at $4.78, while WHSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas WHSI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, EKTAY is more volatile compared to WHSI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check WHSI's competition here
EKTAY vs BLFE Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, EKTAY is priced at $4.78, while BLFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas BLFE's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to BLFE's ROE of +0.00%. Regarding short-term risk, EKTAY is more volatile compared to BLFE. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BLFE's competition here
EKTAY vs CEOS Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, CEOS has a market cap of 119K. Regarding current trading prices, EKTAY is priced at $4.78, while CEOS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas CEOS's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to CEOS's ROE of +1.18%. Regarding short-term risk, EKTAY is more volatile compared to CEOS. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CEOS's competition here
EKTAY vs QTXB Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, EKTAY is priced at $4.78, while QTXB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas QTXB's P/E ratio is -0.05. In terms of profitability, EKTAY's ROE is +0.02%, compared to QTXB's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check QTXB's competition here
EKTAY vs SDCCQ Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SDCCQ has a market cap of 40.3K. Regarding current trading prices, EKTAY is priced at $4.78, while SDCCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, EKTAY is more volatile compared to SDCCQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SDCCQ's competition here
EKTAY vs GMVDF Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, EKTAY is priced at $4.78, while GMVDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas GMVDF's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, EKTAY is more volatile compared to GMVDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check GMVDF's competition here
EKTAY vs ASFX Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, ASFX has a market cap of 17.5K. Regarding current trading prices, EKTAY is priced at $4.78, while ASFX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas ASFX's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, EKTAY is more volatile compared to ASFX. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ASFX's competition here
EKTAY vs INND Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, INND has a market cap of 14.5K. Regarding current trading prices, EKTAY is priced at $4.78, while INND trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas INND's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to INND's ROE of +0.32%. Regarding short-term risk, EKTAY is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check INND's competition here
EKTAY vs MDIT Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, MDIT has a market cap of 8.6K. Regarding current trading prices, EKTAY is priced at $4.78, while MDIT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas MDIT's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, EKTAY is more volatile compared to MDIT. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MDIT's competition here
EKTAY vs LANZ Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, LANZ has a market cap of 4.2K. Regarding current trading prices, EKTAY is priced at $4.78, while LANZ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas LANZ's P/E ratio is 0.15. In terms of profitability, EKTAY's ROE is +0.02%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, EKTAY is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check LANZ's competition here
EKTAY vs DGEN Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, EKTAY is priced at $4.78, while DGEN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas DGEN's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to DGEN. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check DGEN's competition here
EKTAY vs SVSO Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, EKTAY is priced at $4.78, while SVSO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SVSO's P/E ratio is -0.01. In terms of profitability, EKTAY's ROE is +0.02%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, EKTAY is more volatile compared to SVSO. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SVSO's competition here
EKTAY vs LFPI Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, LFPI has a market cap of 2K. Regarding current trading prices, EKTAY is priced at $4.78, while LFPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas LFPI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, EKTAY is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check LFPI's competition here
EKTAY vs SEYE Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, EKTAY is priced at $4.78, while SEYE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SEYE's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to SEYE's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to SEYE. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SEYE's competition here
EKTAY vs BGMD Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, EKTAY is priced at $4.78, while BGMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas BGMD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to BGMD's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to BGMD. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check BGMD's competition here
EKTAY vs ADLI Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, EKTAY is priced at $4.78, while ADLI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas ADLI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, EKTAY is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ADLI's competition here
EKTAY vs VSMD Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, VSMD has a market cap of 801. Regarding current trading prices, EKTAY is priced at $4.78, while VSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas VSMD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, EKTAY is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check VSMD's competition here
EKTAY vs HRAL Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, HRAL has a market cap of 396. Regarding current trading prices, EKTAY is priced at $4.78, while HRAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas HRAL's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to HRAL's ROE of +0.13%. Regarding short-term risk, EKTAY is more volatile compared to HRAL. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check HRAL's competition here
EKTAY vs MICRD Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, MICRD has a market cap of 317. Regarding current trading prices, EKTAY is priced at $4.78, while MICRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas MICRD's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is +0.02%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, EKTAY is more volatile compared to MICRD. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MICRD's competition here
EKTAY vs RGBOQ Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, EKTAY is priced at $4.78, while RGBOQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is +0.02%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to RGBOQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check RGBOQ's competition here
EKTAY vs SECI Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, SECI has a market cap of 31. Regarding current trading prices, EKTAY is priced at $4.78, while SECI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas SECI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to SECI's ROE of -0.00%. Regarding short-term risk, EKTAY is more volatile compared to SECI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SECI's competition here
EKTAY vs VTEQ Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, EKTAY is priced at $4.78, while VTEQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is +0.02%, compared to VTEQ's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to VTEQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check VTEQ's competition here
EKTAY vs OCPNY Comparison August 2025
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.8B. In comparison, OCPNY has a market cap of 0. Regarding current trading prices, EKTAY is priced at $4.78, while OCPNY trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 68.26, whereas OCPNY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.02%, compared to OCPNY's ROE of +0.26%. Regarding short-term risk, EKTAY is more volatile compared to OCPNY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OCPNY's competition here